Home > Boards > US OTC > Biotechs > Fortress BioTechnology (FBIO)

Mustang Bio Announces Full Exercise of Option

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
conix Member Profile
 
Followed By 166
Posts 26,125
Boards Moderated 6
Alias Born 10/10/05
160x600 placeholder
Avenue Therapeutics Announces Submission of New Drug Application for IV Tramadol GlobeNewswire Inc. - 12/11/2019 8:30:10 AM
Avenue Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights GlobeNewswire Inc. - 11/4/2019 7:30:00 AM
Avenue Therapeutics Announces Publication of IV Tramadol Phase 1 Clinical Data in Clinical Pharmacology in Drug Development GlobeNewswire Inc. - 10/28/2019 8:30:05 AM
Avenue Therapeutics to Present Phase 3 Bunionectomy Study of IV Tramadol at the American Society of Anesthesiologists Annual ... GlobeNewswire Inc. - 10/18/2019 8:30:05 AM
Avenue Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights GlobeNewswire Inc. - 8/14/2019 7:30:00 AM
Avenue Therapeutics Announces Appointment of Ms. E. Garrett Ingram to Board of Directors GlobeNewswire Inc. - 8/1/2019 8:00:00 AM
Avenue Therapeutics Announces Positive Topline Data from Second Pivotal Phase 3 Study of Intravenous Tramadol in the Manageme... GlobeNewswire Inc. - 6/3/2019 7:00:00 AM
Avenue Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights GlobeNewswire Inc. - 5/13/2019 7:30:00 AM
Avenue Therapeutics Announces Appointment of Dr. Thomas G. Moore to Board of Directors GlobeNewswire Inc. - 4/30/2019 7:30:00 AM
Market Trends Toward New Normal in Colgate-Palmolive, Nucor, NeoPhotonics, Piper Jaffray Companies, The Ensign Group, and For... GlobeNewswire Inc. - 4/3/2019 8:45:00 AM
Avenue Therapeutics Reports Full Year 2018 Financial Results and Recent Corporate Highlights GlobeNewswire Inc. - 3/12/2019 7:30:00 AM
Avenue Therapeutics Announces First Stage Closing of its Acquisition Agreement with InvaGen (a Cipla subsidiary) GlobeNewswire Inc. - 2/11/2019 7:30:00 AM
Avenue Therapeutics Announces Dosing of First Patient in Second Pivotal Phase 3 Clinical Trial of Intravenous Tramadol for th... GlobeNewswire Inc. - 12/19/2018 8:00:00 AM
conix   Wednesday, 05/08/19 10:35:55 AM
Re: phil anthropist post# 21
Post # of 62 
Mustang Bio Announces Full Exercise of Option

Date: 05-08-2019



NEW YORK, May 08, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that the underwriters of its recent public offering of common stock have exercised in full their option and purchased an additional 1,031,250 shares at the public offering price of $4.00 per share. The exercise of the underwriters' option closed on May 8, 2019, with all of the option shares sold by Mustang. After giving effect to the sale of the option shares, a total of 7,906,250 shares of common stock were offered and sold in the offering.

On April 30, 2019, Mustang priced its public offering of 6,875,000 shares of common stock at $4.00 per share. Following the closing of the exercise of the underwriters' option, Mustang has received aggregate gross proceeds, before deducting underwriting discounts and commissions and offering expenses, of approximately $31.6 million.

Cantor Fitzgerald & Co. acted as lead book running manager for the offering. Oppenheimer & Co. Inc. acted as book running manager, and H.C. Wainwright & Co. and Roth Capital Partners acted as co-managers for the offering.

Mustang intends to use the net proceeds from the offering primarily for the continued development of its product candidates, the potential in-license, acquisition, development and commercialization of other pharmaceutical products and for general corporate purposes.

A shelf registration statement on Form S-3 (File. No. 333-226175) (the “Registration Statement”) relating to the shares of common stock being offered was filed with the U.S. Securities and Exchange Commission (SEC) and was declared effective on July 27, 2018. Copies of the prospectus supplement and accompanying prospectus, may be obtained from Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Ave., 6th Floor, New York, New York 10022, or by e-mail at prospectus@cantor.com; or the on the SEC’s website at http://www.sec.gov.

The offering was made only by means of a prospectus. A final prospectus supplement to the base prospectus describing the terms of the offering was filed with the SEC. This press release shall not constitute an offer to sell or a solicitation of an offer to buy securities of the Company, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale is not permitted.

About Mustang Bio

Mustang Bio, Inc. (“Mustang”) is a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market. Mustang has partnered with top medical institutions to advance the development of CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as a lentiviral gene therapy for XSCID. Mustang is registered under the Securities Exchange Act of 1934, as amended, and files periodic reports with the U.S. Securities and Exchange Commission. Mustang was founded by Fortress Biotech, Inc. (NASDAQ: FBIO).

Successful Trading is the art of minimizing long term risk and maximizing capital allocation.
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist